The estimated Net Worth of Lewis T Williams is at least $25.5 Million dollars as of 5 November 2018. Lewis Williams owns over 91,217 units of Protagonist Therapeutics Inc stock worth over $20,846,610 and over the last 10 years he sold PTGX stock worth over $4,534,403. In addition, he makes $123,841 as Independent Director at Protagonist Therapeutics Inc.
Sign up
Lewis Williams PTGX stock SEC Form 4 insiders trading
Lewis has made over 15 trades of the Protagonist Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 91,217 units of PTGX stock worth $415,950 on 5 November 2018.
The largest trade he's ever made was exercising 91,217 units of Protagonist Therapeutics Inc stock on 5 November 2018 worth over $415,950. On average, Lewis trades about 12,517 units every 29 days since 2014. As of 5 November 2018 he still owns at least 465,430 units of Protagonist Therapeutics Inc stock.
You can see the complete history of Lewis Williams stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lewis Williams biography
Dr. Lewis T. Williams M.D., Ph.D. serves as Independent Director of the Company. He has served as a member of the Board since June 2017. He has served as Chairman and Chief Executive Officer of Walking Fish Therapeutics, a biotechnology start-up company, since February 2019. Dr. Williams has also served as a venture partner of Quan Capital, LLP, a healthcare-focused venture capital firm, since October 2018. Dr. Williams founded and served as a director of Five Prime Therapeutics, Inc., a public biotechnology company, from January 2002 until January 2020, and served as its President and Chief Executive Officer from April 2011 to December 2017. Previously, Dr. Williams spent seven years at Chiron Corporation ("Chiron") a biopharmaceutical company, now known as Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer. He also served on Chiron's board of directors from 1999 to 2001. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco, and served as Director of the University's Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams has served as a member of the board of directors of Neoleukin Pharmaceuticals, a public biopharmaceutical company, since September 2019. He was previously a member of the board of directors of COR Therapeutics, Inc., and Beckman Coulter, Inc., each of which was a public company during his service as a director. Dr. Williams also currently serves on the board of directors of a privately-held company. He received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.
What is the salary of Lewis Williams?
As the Independent Director of Protagonist Therapeutics Inc, the total compensation of Lewis Williams at Protagonist Therapeutics Inc is $123,841. There are 10 executives at Protagonist Therapeutics Inc getting paid more, with Dinesh Patel having the highest compensation of $1,948,340.
How old is Lewis Williams?
Lewis Williams is 70, he's been the Independent Director of Protagonist Therapeutics Inc since 2017. There are 1 older and 19 younger executives at Protagonist Therapeutics Inc. The oldest executive at Protagonist Therapeutics Inc is Dr. David Y. Liu, 71, who is the Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel..
What's Lewis Williams's mailing address?
Lewis's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160.
Insiders trading at Protagonist Therapeutics Inc
Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson..., and X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.
What does Protagonist Therapeutics Inc do?
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
What does Protagonist Therapeutics Inc's logo look like?
Complete history of Lewis Williams stock trades at Five Prime Therapeutics Inc, Protagonist Therapeutics Inc, and Neoleukin Therapeutics
Protagonist Therapeutics Inc executives and stock owners
Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dinesh Patel,
President, Chief Executive Officer, Director -
Suneel Gupta,
Chief Development Officer -
David Liu,
Chief Scientific Officer, Head of Research & Development -
Dr. Dinesh V. Patel Ph.D.,
CEO, Pres, Interim PAO, Sec. & Director -
Dr. David Y. Liu,
Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel. -
Dr. Suneel K. Gupta Ph.D.,
Chief Devel. Officer -
Harold Selick,
Independent Chairman of the Board -
William Waddill,
Independent Director -
Bryan Giraudo,
Independent Director -
Sarah Noonberg,
Independent Director -
Lewis Williams,
Independent Director -
Sarah O'Dowd,
Independent Director -
Brian Korb,
IR Contact Officer -
Samuel Saks,
Chief Medical Officer -
Donald Kalkofen,
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer -
Asif Ali,
Exec. VP & Chief Financial Officer -
Dr. Scott Eric Plevy M.D.,
Exec. VP and Therapeutic Head of Gastroenterology -
Dr. Ashok Bhandari Ph.D.,
Sr. VP of Discovery Chemistry & Process Research -
Mohammad Masjedizadeh,
Exec. VP & CTO -
Donald A. Kalkofen,
Chief Financial Officer -
Dr. Larry Mattheakis,
Sr. VP of Discovery Biology & Translational Research -
Dr. Ashok Bhandari,
Sr. VP of Discovery Chemistry & Process Research -
Carena Spivey,
Exec. Director of HR -
Matthew M. Gosling,
Exec. VP & Gen. Counsel -
Dr. Mark Smythe,
Founder & VP Technology -
Dr. Richard S. Shames,
Clinical Advisor -
Arturo Md Molina,
Chief Medical Officer -
Armen Shanafelt,
Director -
Chaitan Phd Khosla,
Director -
Julie Papanek,
Director -
Richard S. Shames,
Chief Medical Officer -
Thomas P. O'neil,
Chief Financial Officer -
William A Hodder,
Sr. VP - Corporate Development -
& Johnson Johnson & Johnson...,
-
X L.P.Canaan Partners X Llc...,
-
Management Group, Llc Lilly...,
-
Asif Ali,
Chief Financial Officer -
Capital Partners Gp, L.L.C....,
-
Daniel N Jr Swisher,
Director